This company has been marked as potentially delisted and may not be actively trading.

Bionomics (BNOX) Competitors

BNOX vs. KTTA, GNTA, NAII, LEXX, and PASG

Should you be buying Bionomics stock or one of its competitors? The main competitors of Bionomics include Pasithea Therapeutics (KTTA), Genenta Science (GNTA), Natural Alternatives International (NAII), Lexaria Bioscience (LEXX), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry.

How does Bionomics compare to Pasithea Therapeutics?

Bionomics (NASDAQ:BNOX) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

: Bionomics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.
: 15.9% of Bionomics shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 0.7% of Bionomics shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
: In the previous week, Pasithea Therapeutics had 2 more articles in the media than Bionomics. MarketBeat recorded 2 mentions for Pasithea Therapeutics and 0 mentions for Bionomics. Pasithea Therapeutics' average media sentiment score of 0.69 beat Bionomics' score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
Bionomics Neutral
Pasithea Therapeutics Positive
: Bionomics has higher revenue and earnings than Pasithea Therapeutics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionomics $10K 446.82 -$15.49M N/A N/A
Pasithea Therapeutics N/A N/A -$20.43M -$3.57 N/A
: Pasithea Therapeutics has a consensus price target of $3.00, indicating a potential upside of 251.29%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Bionomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionomics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Pasithea Therapeutics
2 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
1.67
: Bionomics' return on equity of 0.00% beat Pasithea Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Bionomics N/A N/A N/A
Pasithea Therapeutics N/A -85.48% -77.42%

Company	Overall Sentiment
Bionomics	Neutral
Pasithea Therapeutics	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionomics	$10K	446.82	-$15.49M	N/A	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionomics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Company	Net Margins	Return on Equity	Return on Assets
Bionomics	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-85.48%	-77.42%

Summary

Pasithea Therapeutics beats Bionomics on 7 of the 12 factors compared between the two stocks.

How does Bionomics compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

: Genenta Science has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Comparatively, Bionomics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.
: In the previous week, Genenta Science's average media sentiment score of 0.00 equaled Bionomics'average media sentiment score.
Company Overall Sentiment
Genenta Science Neutral
Bionomics Neutral
: 15.1% of Genenta Science shares are held by institutional investors. Comparatively, 15.9% of Bionomics shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 0.7% of Bionomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Genenta Science has higher earnings, but lower revenue than Bionomics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genenta Science N/A N/A -$7.39M N/A N/A
Bionomics $10K 446.82 -$15.49M N/A N/A
: Company Net Margins Return on Equity Return on Assets
Genenta Science N/A N/A N/A
Bionomics N/A N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Bionomics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Genenta Science	Neutral
Bionomics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Bionomics	$10K	446.82	-$15.49M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Bionomics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionomics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Genenta Science beats Bionomics on 4 of the 6 factors compared between the two stocks.

How does Bionomics compare to Natural Alternatives International?

Natural Alternatives International (NASDAQ:NAII) and Bionomics (NASDAQ:BNOX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

: Natural Alternatives International has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Bionomics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.
: In the previous week, Natural Alternatives International had 1 more articles in the media than Bionomics. MarketBeat recorded 1 mentions for Natural Alternatives International and 0 mentions for Bionomics. Natural Alternatives International's average media sentiment score of 0.00 equaled Bionomics'average media sentiment score.
Company Overall Sentiment
Natural Alternatives International Neutral
Bionomics Neutral
: 32.4% of Natural Alternatives International shares are held by institutional investors. Comparatively, 15.9% of Bionomics shares are held by institutional investors. 20.8% of Natural Alternatives International shares are held by company insiders. Comparatively, 0.7% of Bionomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Natural Alternatives International has higher revenue and earnings than Bionomics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Natural Alternatives International $135.16M 0.13 -$13.57M -$2.04 N/A
Bionomics $10K 446.82 -$15.49M N/A N/A
: Bionomics has a net margin of 0.00% compared to Natural Alternatives International's net margin of -9.06%. Bionomics' return on equity of 0.00% beat Natural Alternatives International's return on equity.
Company Net Margins Return on Equity Return on Assets
Natural Alternatives International -9.06% -8.60% -3.92%
Bionomics N/A N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natural Alternatives International
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Bionomics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Natural Alternatives International	Neutral
Bionomics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Natural Alternatives International	$135.16M	0.13	-$13.57M	-$2.04	N/A
Bionomics	$10K	446.82	-$15.49M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Natural Alternatives International	-9.06%	-8.60%	-3.92%
Bionomics	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Natural Alternatives International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionomics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Natural Alternatives International beats Bionomics on 7 of the 11 factors compared between the two stocks.

How does Bionomics compare to Lexaria Bioscience?

Bionomics (NASDAQ:BNOX) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

: Bionomics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
: Bionomics has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,685.84%. Bionomics' return on equity of 0.00% beat Lexaria Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Bionomics N/A N/A N/A
Lexaria Bioscience -1,685.84% -206.02% -162.53%
: 15.9% of Bionomics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 0.7% of Bionomics shares are owned by insiders. Comparatively, 8.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: In the previous week, Bionomics' average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.
Company Overall Sentiment
Bionomics Neutral
Lexaria Bioscience Neutral
: Lexaria Bioscience has a consensus target price of $1.50, indicating a potential upside of 124.55%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Lexaria Bioscience is more favorable than Bionomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionomics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Lexaria Bioscience
1 Sell rating(s)

0 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: Lexaria Bioscience has higher revenue and earnings than Bionomics.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionomics $10K 446.82 -$15.49M N/A N/A
Lexaria Bioscience $710K 23.32 -$11.90M -$0.47 N/A

Company	Net Margins	Return on Equity	Return on Assets
Bionomics	N/A	N/A	N/A
Lexaria Bioscience	-1,685.84%	-206.02%	-162.53%

Company	Overall Sentiment
Bionomics	Neutral
Lexaria Bioscience	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionomics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionomics	$10K	446.82	-$15.49M	N/A	N/A
Lexaria Bioscience	$710K	23.32	-$11.90M	-$0.47	N/A

Summary

Lexaria Bioscience beats Bionomics on 7 of the 12 factors compared between the two stocks.

How does Bionomics compare to Passage Bio?

Bionomics (NASDAQ:BNOX) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

: Bionomics has a beta of 0.26, meaning that its share price is 74% less volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
: Bionomics' return on equity of 0.00% beat Passage Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Bionomics N/A N/A N/A
Passage Bio N/A -135.04% -60.37%
: 15.9% of Bionomics shares are held by institutional investors. Comparatively, 53.5% of Passage Bio shares are held by institutional investors. 0.7% of Bionomics shares are held by insiders. Comparatively, 4.9% of Passage Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: In the previous week, Passage Bio had 1 more articles in the media than Bionomics. MarketBeat recorded 1 mentions for Passage Bio and 0 mentions for Bionomics. Bionomics' average media sentiment score of 0.00 equaled Passage Bio'saverage media sentiment score.
Company Overall Sentiment
Bionomics Neutral
Passage Bio Neutral
: Passage Bio has a consensus price target of $13.25, indicating a potential upside of 213.54%. Given Passage Bio's stronger consensus rating and higher possible upside, analysts clearly believe Passage Bio is more favorable than Bionomics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bionomics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Passage Bio
1 Sell rating(s)

4 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.14
: Bionomics has higher revenue and earnings than Passage Bio.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bionomics $10K 446.82 -$15.49M N/A N/A
Passage Bio N/A N/A -$45.52M -$14.48 N/A

Company	Net Margins	Return on Equity	Return on Assets
Bionomics	N/A	N/A	N/A
Passage Bio	N/A	-135.04%	-60.37%

Company	Overall Sentiment
Bionomics	Neutral
Passage Bio	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionomics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Passage Bio	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionomics	$10K	446.82	-$15.49M	N/A	N/A
Passage Bio	N/A	N/A	-$45.52M	-$14.48	N/A

Summary

Passage Bio beats Bionomics on 7 of the 11 factors compared between the two stocks.

Get Bionomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNOX vs. The Competition

Export

Metric	Bionomics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.47M	$901.41M	$6.28B	$12.14B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	N/A	1.73	28.70	27.32
Price / Sales	446.82	119.57	524.01	84.57
Price / Cash	N/A	20.07	43.42	54.56
Price / Book	0.19	7.67	9.89	6.77
Net Income	-$15.49M	-$4.80M	$3.55B	$332.68M

Bionomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNOX Bionomics	N/A	$0.25 flat	N/A	N/A	$4.47M	$10K	N/A	N/A
KTTA Pasithea Therapeutics	2.4833 of 5 stars	$0.84 +21.1%	$3.00 +256.7%	-44.1%	$17.33M	N/A	N/A	3	High Trading Volume
GNTA Genenta Science	0.8402 of 5 stars	$0.73 +2.6%	N/A	-83.8%	$16.78M	N/A	N/A	7
NAII Natural Alternatives International	1.0631 of 5 stars	$2.72 +1.9%	N/A	+0.7%	$16.49M	$129.86M	N/A	290	Upcoming Earnings
LEXX Lexaria Bioscience	1.8298 of 5 stars	$0.71 +7.9%	$1.50 +110.9%	-37.6%	$16.33M	$710K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNOX) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionomics (BNOX) Competitors

BNOX vs. KTTA, GNTA, NAII, LEXX, and PASG

How does Bionomics compare to Pasithea Therapeutics?

Summary

How does Bionomics compare to Genenta Science?

Summary

How does Bionomics compare to Natural Alternatives International?

Summary

How does Bionomics compare to Lexaria Bioscience?

Summary

How does Bionomics compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNOX vs. The Competition

Bionomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionomics (BNOX) Competitors

BNOX vs. KTTA, GNTA, NAII, LEXX, and PASG

How does Bionomics compare to Pasithea Therapeutics?

Summary

How does Bionomics compare to Genenta Science?

Summary

How does Bionomics compare to Natural Alternatives International?

Summary

How does Bionomics compare to Lexaria Bioscience?

Summary

How does Bionomics compare to Passage Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNOX vs. The Competition

Bionomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools